COVID-19 in congenital heart disease (COaCHeD) study.
COVID-19
EPIDEMIOLOGY
Heart Defects, Congenital
RISK FACTORS
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
02
05
2023
accepted:
23
06
2023
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
COVID-19 has caused significant worldwide morbidity and mortality. Congenital heart disease (CHD) is likely to increase vulnerability and understanding the predictors of adverse outcomes is key to optimising care. Ascertain the impact of COVID-19 on people with CHD and define risk factors for adverse outcomes. Multicentre UK study undertaken 1 March 2020-30 June 2021 during the COVID-19 pandemic. Data were collected on CHD diagnoses, clinical presentation and outcomes. Multivariable logistic regression with multiple imputation was performed to explore predictors of death and hospitalisation. There were 405 reported cases (127 paediatric/278 adult). In children (age <16 years), there were 5 (3.9%) deaths. Adjusted ORs (AORs) for hospitalisation in children were significantly lower with each ascending year of age (OR 0.85, 95% CI 0.75 to 0.96 (p<0.01)). In adults, there were 24 (8.6%) deaths (19 with comorbidities) and 74 (26.6%) hospital admissions. AORs for death in adults were significantly increased with each year of age (OR 1.05, 95% CI 1.01 to 1.10 (p<0.01)) and with pulmonary arterial hypertension (PAH; OR 5.99, 95% CI 1.34 to 26.91 (p=0.02)). AORs for hospitalisation in adults were significantly higher with each additional year of age (OR 1.03, 95% CI 1.00 to 1.05 (p=0.04)), additional comorbidities (OR 3.23, 95% CI 1.31 to 7.97 (p=0.01)) and genetic disease (OR 2.87, 95% CI 1.04 to 7.94 (p=0.04)). Children were at low risk of death and hospitalisation secondary to COVID-19 even with severe CHD, but hospital admission rates were higher in younger children, independent of comorbidity. In adults, higher likelihood of death was associated with increasing age and PAH, and of hospitalisation with age, comorbidities and genetic disease. An individualised approach, based on age and comorbidities, should be taken to COVID-19 management in patients with CHD.
Sections du résumé
BACKGROUND
COVID-19 has caused significant worldwide morbidity and mortality. Congenital heart disease (CHD) is likely to increase vulnerability and understanding the predictors of adverse outcomes is key to optimising care.
OBJECTIVE
Ascertain the impact of COVID-19 on people with CHD and define risk factors for adverse outcomes.
METHODS
Multicentre UK study undertaken 1 March 2020-30 June 2021 during the COVID-19 pandemic. Data were collected on CHD diagnoses, clinical presentation and outcomes. Multivariable logistic regression with multiple imputation was performed to explore predictors of death and hospitalisation.
RESULTS
There were 405 reported cases (127 paediatric/278 adult). In children (age <16 years), there were 5 (3.9%) deaths. Adjusted ORs (AORs) for hospitalisation in children were significantly lower with each ascending year of age (OR 0.85, 95% CI 0.75 to 0.96 (p<0.01)). In adults, there were 24 (8.6%) deaths (19 with comorbidities) and 74 (26.6%) hospital admissions. AORs for death in adults were significantly increased with each year of age (OR 1.05, 95% CI 1.01 to 1.10 (p<0.01)) and with pulmonary arterial hypertension (PAH; OR 5.99, 95% CI 1.34 to 26.91 (p=0.02)). AORs for hospitalisation in adults were significantly higher with each additional year of age (OR 1.03, 95% CI 1.00 to 1.05 (p=0.04)), additional comorbidities (OR 3.23, 95% CI 1.31 to 7.97 (p=0.01)) and genetic disease (OR 2.87, 95% CI 1.04 to 7.94 (p=0.04)).
CONCLUSIONS
Children were at low risk of death and hospitalisation secondary to COVID-19 even with severe CHD, but hospital admission rates were higher in younger children, independent of comorbidity. In adults, higher likelihood of death was associated with increasing age and PAH, and of hospitalisation with age, comorbidities and genetic disease. An individualised approach, based on age and comorbidities, should be taken to COVID-19 management in patients with CHD.
Identifiants
pubmed: 37460271
pii: openhrt-2023-002356
doi: 10.1136/openhrt-2023-002356
pmc: PMC10357297
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : British Heart Foundation
ID : FS/11/38/28864
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Ann Intern Med. 2021 Mar;174(3):362-373
pubmed: 33253040
J Am Coll Cardiol. 2021 Apr 6;77(13):1644-1655
pubmed: 33795039
BMJ Open. 2016 Nov 15;6(11):e012750
pubmed: 27852716
Pediatr Cardiol. 2020 Oct;41(7):1391-1401
pubmed: 32529358
Pediatr Cardiol. 2022 Mar;43(3):541-546
pubmed: 34633493
Heart. 2021 Mar 8;:
pubmed: 33685931
J Clin Med. 2020 Jun 08;9(6):
pubmed: 32521643
Ann Pediatr Cardiol. 2021 Jul-Sep;14(3):269-277
pubmed: 34667396
J Am Heart Assoc. 2020 Dec;9(23):e017580
pubmed: 33196343
Lancet Child Adolesc Health. 2020 Sep;4(9):669-677
pubmed: 32653054
Cardiol Young. 2022 Aug;32(8):1261-1267
pubmed: 34588090
J Pediatr. 2020 Oct;225:246-248
pubmed: 32610168
Cardiol Young. 2021 Jan;31(1):163-165
pubmed: 33308340